报价延迟最少15分钟:2025/11/19 12:33 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.48 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.23/-5.17
|
|
企业价值
11.18M
|
| 资产负债 |
|
每股账面净值
8.06
|
| 现金流量 |
|
现金流量率
0.01
|
| 损益表 |
|
收益
0
|
|
每股收益
0.00
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/19 12:33 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorderswith high unmet medical need. |
